Levobel Diario

Ethinylestradiol, the active ingredient in Levobel Diario, is a combined oral contraceptive presented as a tablet for oral use. Together with levonorgestrel, it provides hormonal contraception for women of reproductive age, preventing ovulation and altering cervical mucus. The product complies with EU pharmaceutical standards and contains lactose as an inactive filler.

GNH USA supplies Levobel Diario as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring consistent quality and regulatory conformity for global distribution to meet local market requirements.

Levobel Diario, a combined oral contraceptive, is used for hormonal contraception in women. - Contraception (prevention of pregnancy): provides reliable hormonal birth control for women of reproductive age. - Menstrual cycle regulation: helps establish regular menstrual bleeding patterns and reduces cycle‑related discomfort. - Acne associated with androgen excess: decreases androgen activity, leading to improvement of acne lesions. - Endometriosis symptom management: reduces menstrual pain and lesion growth. - Polycystic ovary syndrome (PCOS) symptom control: assists in regulating ovulation and androgen levels.

Levobel Diario may cause a range of adverse reactions, varying from common and mild to serious but rare.

Common Side Effects: - Nausea: mild to moderate stomach upset, especially during the first cycles. - Breast tenderness: temporary swelling or discomfort of the breasts. - Headache: mild to moderate headaches that often improve with continued use. - Spotting or breakthrough bleeding: irregular light bleeding between periods.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs, requiring immediate medical attention. - Arterial thrombosis: clot formation in arteries, which can lead to stroke or heart attack. - Severe allergic reaction: rash, swelling, or difficulty breathing indicating possible anaphylaxis.

Before prescribing Levobel Diario, healthcare professionals should evaluate several safety considerations. - Assess cardiovascular risk: review history of thrombosis, hypertension, or smoking before initiation. - Evaluate hepatic function: avoid use in patients with active liver disease or severe liver dysfunction. - Review medication history: consider interactions with enzyme‑inducing drugs that may reduce efficacy. - Counsel on smoking: advise women over 35 who smoke to discontinue use due to increased clot risk. - Monitor for signs of thromboembolism: educate patients to seek urgent care for leg pain, swelling, or chest discomfort. - Store at ambient temperature: keep tablets below 25 °C in the original packaging, protected from moisture and light.

Levobel Diario can interact with other medicines, affecting its contraceptive effectiveness or safety profile.

Major Interactions (Avoid): - Strong enzyme inducers (e.g., rifampin, carbamazepine, phenytoin): markedly reduce hormone levels, compromising contraception. - Combined hormonal therapy for breast cancer: concurrent use is contraindicated due to opposing hormonal actions.

Moderate Interactions (Monitor Closely): - Antifungal azoles (e.g., ketoconazole, itraconazole): may increase estrogen levels, raising risk of side effects. - Anticonvulsants (e.g., valproate, topiramate): can alter hormone metabolism, requiring additional contraceptive measures. - Herbal supplements (e.g., St. John’s wort): may decrease contraceptive efficacy, advise monitoring or backup method.